Seres Therapeutics (MCRB) Files for $100M IPO

Seres Therapeutics, Inc. (Nasdaq: MCRB) filed a registration with the U.S. SEC for an IPO of its Common Stock. The proposed maximum offering price is $100 million. The company plans to list on the Nasdaq Global Market under the ticker, MCRB.

Underwriters are Goldman, Sachs & Co., BofA Merrill Lynch, Leerink Partners, and Canaccord Genuity.

Seres Therapeutics is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics.

You May Also Be Interested In

• Fabric.AI stockholders approve Kopin partnership for MicroLED interconnect
• LataMed AI signs deal with Caracas fitness operator Focus Fitness
• GD Culture Group prices $5.45M stock offering at $0.021 per share